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Military personnel are returning from Iraq andAfghanistan and reporting non-speciﬁc physi-
cal (somatic), behavioral, psychological, and cognitive symptoms.Many of these symptoms
are frequently associated with mild traumatic brain injury (mTBI) and/or post traumatic
stress disorder (PTSD). Despite signiﬁcant attention and advances in assessment and
intervention for these two conditions, challenges persist. To address this, clinically rele-
vant blast models are essential in the full characterization of this type of injury, as well as
in the testing and identiﬁcation of potential treatment strategies. In this publication, exist-
ing diagnostic challenges and current treatment practices for mTBI and/or PTSD will be
summarized, along with suggestions regarding how what has been learned from existing
models of PTSD and traditional mechanism (e.g., non-blast) traumatic brain injury can be
used to facilitate the development of clinically relevant blast models.
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INTRODUCTION
Findings suggest that explosive mechanisms (e.g., improvised
explosive devices [IEDs], rocket-propelled grenades [RPGs])
account for 56–78% of injuries being sustained by military per-
sonnel serving in Iraq and Afghanistan (Owens et al., 2008; Sayer
et al., 2008). Following exposure, individuals are reporting a range
of non-speciﬁc physical, psychological, and behavioral symptoms
including headaches, decreased sleep, fatigue, depressed and anx-
ious mood, and problems with concentration and memory. For
many, symptoms are also accompanied by decreased psychoso-
cial functioning (e.g., poor work performance, increased conﬂicts
with signiﬁcant others). Clinical presentation following exposure
to blast is heterogeneous, and appears to be dependent on a wide-
range of contextual factors (e.g., proximity to the blast, whether or
not the individual sustained other injuries). Pre-existing individ-
ual differences (e.g., history of childhood trauma, social support)
further contribute to variations in presentation. Unfortunately,
these individual and contextual factors are not alone in contribut-
ing to diagnostic and treatment challenges. Wide-ranging limi-
tations in existing knowledge – such as the physiological impact
of blast exposure on humans, and means of objectively assess-
ing history of mild traumatic brain injury (mTBI; Brenner et al.,
2009; Brenner, 2011) – further impede effective assessment and
intervention.
Nevertheless, based on evidence from the acute and post-acute
clinical presentation of military personnel returning from battle
and animal models (Cernak et al., 2011; Koliatsos et al., 2011)
existing efforts have focused on two conditions, mTBI and post
traumatic stress disorder (PTSD). This is in part related to the rates
of these conditions being reported in returning military person-
nel. The percent of individuals among speciﬁed military cohorts
reporting a history of mTBI varies widely (8–23%) and appears
to be dependent upon multiple factors (e.g., time served, combat
exposure, Military Occupational Specialty [MOS; Vasterling et al.,
2006; Terrio et al., 2009]). Data also suggests that among those
with a military–related mTBI the rate of symptoms associated
with the injury reported decreases over time (Terrio et al., 2009).
Rates of PTSD appear to also vary. Findings from a population-
based study of previously deployed OEF/OIF military personnel
suggested that the prevalence rate of PTSD was 13.8% (Tanielian
and Jaycox, 2008). Recent work by the Armed Forces Health Sur-
veillance Center (2011) suggested that in every gender, age, and
MOS subgroup, larger percentages of those who deployed were
diagnosed with PTSD and anxiety-related disorders after the sec-
ond and/or third deployment versus the ﬁrst. Using Department
of VeteransAffairs administrative data,Maguen et al. (2010) found
that 17% of female and 22% of male OEF/OIF Veterans seeking
VA health care were diagnosed with PTSD. The goal of this pub-
lication is to brieﬂy summarize existing diagnostic challenges and
current treatment practices for mTBI and/or PTSD, with the aim
of highlighting the importance of creating clinically relevant blast
models. Commentary on how existing work in the areas of PTSD
and traditionalmechanism (e.g.,non-blast) traumatic brain injury
(TBI) can be used to facilitate such development is also provided.
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MILD TBI AND PTSD: DIAGNOSTIC CRITERIA
To meet diagnostic criteria for TBI one must have experienced an
event (e.g., blast exposure, motor vehicle accident) which results
in a structural injury to the brain or a physiological disruption of
brain function (alteration of consciousness [AOC], loss of con-
sciousness [LOC]). Severity of TBI is classiﬁed according to the
extent of injury to the brain or altered consciousness post-injury,
versus sequelae reported or observed post-exposure. According
to the American Congress of Rehabilitation Medicine to meet
diagnostic criteria for mTBI one must have had a traumatically
induced physiological disruption of brain function as manifested
by at least one of the following: (1) any period of LOC; (2) any loss
of memory for events immediately before or after the injury; (3)
any alteration in mental state at the time of the injury (e.g., feeling
dazed, disoriented, and confused); and/or (4) focal neurological
deﬁcits that may or may not be transient (Kay et al., 1993). At the
same time, the followingmust not be exceeded: (1) LOCof 30min;
(2) after 30min, Glasgow Coma Scale score of 13–15; and/or (3)
post traumatic amnesia (PTA) of 24 h (Kay et al., 1993).
Similarly, to meet criteria for PTSD an individual must be
exposed to a traumatic event, however, in this case the nature
of the“injury” is psychological versus physiological. Moreover, the
diagnosis of PTSD is based on the emergence of persistent symp-
toms which cause signiﬁcant distress and impact functioning over
time. The Diagnostic and Statistic Manual of Mental Disorders-
IV (DSM-IV; American Psychiatric Association, 2000) deﬁnes a
“traumatic event” as one in which “(1) the person experienced,
witnessed, or was confronted with an event or events that involved
actual or threateneddeath or serious injury,or a threat to the physi-
cal integrity of self or others; and (2) the person’s response involved
intense fear, helplessness, or horror” (p. 427–428). PTSD symp-
toms are clustered into three categories including re-experiencing
of the traumatic event, avoidance of trauma-related stimuli and/or
emotional numbing, and hyperarousal.
MILD TBI AND PTSD: SYMPTOMS
The constellation of symptoms present after blast-induced mTBI,
often called post-concussive symptoms (PCS), are similar to those
reported by individuals with traditional mechanism TBI and
include physical (somatic), behavioral, psychological, and cog-
nitive complaints (i.e., headaches, balance problems, dizziness,
fatigue, irritability, and poor memory and concentration; Terrio
et al., 2009). Further discussion of cognitive-related symptoms is
available in recently published articles (Sayer et al., 2008; Belanger
et al., 2009, 2011; Lippa et al., 2010). Although data from civil-
ian traditional mechanism mTBI populations suggest that most
individuals return baseline functioning within a year (Alexander,
1995), for some PCS persist and lead to decreased psychosocial
functioning (Belanger et al., 2005). As with other types of TBI,
PCS following blast-induced TBI may be staggered in their onset,
ﬂuctuate in severity, and be triggered by life stressors months after
injury (Hicks et al., 2010). The underlying causes and mecha-
nisms of these symptoms are likely multi-factorial (e.g., neuro-
logical changes in the brain, damage to sensory organs, and stress
responses). That is, the extent to which blast-induced neurological
changes account for these symptoms is unclear. While some stud-
ies have found greater symptom complaints in those with more
severe injuries (McLean et al., 1993; Masson et al., 1996) the sever-
ity of blast exposure necessary to cause persistent symptoms has
not been clearly identiﬁed (Hicks et al., 2010). Likewise, compre-
hensive investigation into the effects of repeated blast exposure has
yet to be conducted; though it has been shown that recovery from
PCS occurs more slowly with repeated TBIs (Hicks et al., 2010).
While discerning a reliable anddistinct proﬁle for blast-induced
TBI is complicated, one distinct feature of blast-induced TBI
emerging in the literature is the presence of auditory complica-
tions, namely hearing loss and tinnitus (Lew et al., 2007; Belanger
et al., 2011). A study by Belanger et al. (2011) showed that the only
PCS symptom to differentiate between those sustaining a blast-
induced mTBI and those who had a non-blast induced mTBI was
hearing difﬁculties. Similarly,Wilk et al. (2010) found higher levels
of headache and tinnitus, in those with blast mTBI compared to
those without a blast-related injury.
An increased incidence of PTSD symptoms has also been noted
following blast exposure (Hoge et al., 2008; Belanger et al., 2009).
Although PTSD symptoms are clustered into speciﬁc three cate-
gories, individual expression of these symptoms varies. Whereas
one Veteran may only re-experience traumatic combat experi-
ences while asleep, another may report ﬂashbacks being triggered
by sounds and smells encountered at work or school. Moreover,
returning military personnel with PTSD are also endorsing cog-
nitive and somatic complaints (Hoge et al., 2007; Brenner et al.,
2010). Given the signiﬁcant overlap in the diagnostic features of
PTSD with PCS, it can be challenging to differentiate between
symptoms caused by severe stress and/ormildTBI. Symptomattri-
bution canmade evenmore difﬁcult when relying on retrospective
accounts of injury events (Hicks et al., 2010; Belanger et al., 2011).
That is, clinicians working with returning military personnel are
often attempting to piece together histories from events which
occurred months to years prior.
TBI AND PTSD: EMERGING EVIDENCED REGARDING
CO-OCCURRENCE
Presentation of symptoms following blast-induced TBI is fre-
quently complicated by co-morbid psychiatric conditions, such
as PTSD. There is a likelihood that affective symptoms associ-
ated with PTSD will interact with the PCS and other physical
symptomatology to potentially worsen outcomes. For example,
Brenner et al. (2010) found that in Soldiers with histories of phys-
ical injury, mTBI, and PTSD were independently associated with
PCS. Moreover, a combination of the conditions was found to
be more strongly associated with PCS than either condition alone.
Emerging research also suggests that a history of TBI increases risk
for developing PTSD. Bryant et al. (2010) hypothesize that dam-
age to the frontal regions of the brain may compromise neural
networks which are required to regulate emotional experiences
and as such predispose such patients to increased anxiety and
depression (Bryant et al., 2010).
CURRENT TREATMENTS
TRAUMATIC BRAIN INJURY
There is great need for effective TBI interventions across all
severities – perhaps even more so for mTBI given its preva-
lence. Unfortunately, clinically tested neuroprotective therapies
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in moderate-severe TBI have been disappointing, even after pre-
clinical investigation in animal models (Margulies and Hicks,
2009). As well, the rigor of available studies of symptom-targeted
therapies during post-acute TBI, even in mild cases, does not allow
for the development of deﬁnitive treatment standards (Warden
et al., 2006). That said, a few avenues look promising. First, the
importance of combination therapies is a new driving force in the
development of pharmacological interventions for complicated
mild to severe TBI, including the statins (Margulies and Hicks,
2009) and citicoline (Zafonte et al., 2009). Second, progesterone is
the only pharmacotherapy that has thus far emerged successfully
from animal model to clinical trial (Sayeed and Stein, 2009) with
early signs of the drug being safe and likely beneﬁcial in the acute
post-TBI period among those with moderate to severe injuries
(Wright et al., 2007). A multi-center, placebo controlled Phase
III trial of progesterone is ongoing. Third, non-pharmacological
interventions have also been found to improve outcomes. This was
seen following telephone intervention trials in mild to severe TBI,
in which the intervention was associated with improved overall
function, functional status, quality of life, and depression mea-
sures in comparison to a control group with standard follow-up
(Bell et al., 2005, 2008; Bombardier et al., 2009). Functional bene-
ﬁts were also reported in a placebo controlled trial of acupressure
in post-acute mild TBI (McFadden et al., 2010).
PSYCHOSOCIAL INTERVENTIONS FOR PTSD
In the past two decades there have been substantial advances
in the development of evidence-based psychological treatments
for PTSD. Components of effective PTSD treatments include an
element of exposure and/or cognitive restructuring. Variants of
exposure therapy, including prolonged-exposure therapy (PE; Foa
et al., 2007) have received the most empirical evidence for their
efﬁcacy in treating PTSD. The overall aim of PE is to help trauma
survivors emotionally process their traumatic experiences in order
to reduce PTSD and other trauma-related symptoms (Foa et al.,
2007). This is accomplished through repeated exposure (imaginal
and/or in vivo) to the traumatic memory, which results in habit-
uation of the fear response, allowing the individual to process the
trauma memory and regain mastery of their thoughts and feelings
around the incident.
Cognitive-processing therapy (CPT; Resick et al., 2010), a form
of cognitive behavioral therapy, has also been shown to be highly
efﬁcacious in treating PTSD. CPT is based on social cognitive the-
ory which is focused more on the content of cognitions and the
effect that distorted thoughts may have on emotional responses
(Resick et al., 2010). In this vein, CPT through the use of various
cognitive strategies, helps individuals alter distorted or maladap-
tive beliefs related to the traumatic event, which then creates a
change in the emotional response associated with the trauma.
PSYCHOPHARMACOLOGICAL TREATMENT FOR PTSD
Empirical research on effective pharmacotherapy for PTSD has
produced mixed ﬁndings. This is in part due to the fact that
clinical presentation in PTSD is quite variable and individuals
with PTSD often present with other psychiatric co-morbidities.
Despite these complexities, advances in neurobiology have shed
some light on the relevant neurobiological systems implicated in
PTSD, which has prompted the investigation of pharmacological
agents to target these systems in order to alleviate PTSD symp-
toms (Albucher and Liberzon, 2002; Friedman and Davidson,
2007). The body of evidence on pharmacological treatment of
PTSD suggests that antidepressants demonstrate the best over-
all efﬁcacy for the treatment of PTSD (Albucher and Liberzon,
2002). Of the various classes of antidepressants, selective serotonin
reuptake inhibitors (SSRIs) compared to tricyclic antidepressants
(TCAs) and monoamine oxidase inhibitors (MAOIs) appear to be
the treatment of choice for PTSD (Albucher and Liberzon, 2002;
American Psychiatric Association Steering Committee on Practice
Guidelines, 2004; Management of Post-Traumatic Stress Working
Group, 2010). This is largely due to their demonstrated efﬁcacy
across several large controlled trials, their greater ease of use, lower
risk of overdose, and fewer side effects (Albucher and Liberzon,
2002). Other medications, such as mood stabilizers, atypical neu-
roleptics, and newer antidepressants also show promise; however,
further controlled trials are needed to clarify their efﬁcacy for spe-
ciﬁc PTSD symptoms (Albucher and Liberzon, 2002; Friedman
and Davidson, 2007).
TBI AND PTSD
While there are effective treatments for PTSD and some poten-
tially on the horizon for mTBI, there is unfortunately a dearth of
evidence-based treatments for those with these co-morbid con-
ditions (Soo and Tate, 2007). In the interim, expert consensus
supports providing those with mTBI plus PTSD the two best
evidence-based treatments in the Department of Veterans Affairs
and Department of Defense practice guidelines for PTSD, PE, or
CPT (National Center for Posttraumatic Stress Disorder, 2010).
CLINICAL REALITIES AND BLAST MODELING
MODELING OF TRADITIONAL MECHANISM TBI: CHALLENGES AND
LESSONS LEARNED
Developing animal models of TBI poses many challenges. Animal
studies often involve injury to only the brain, in precise regions
and without co-occurring physical insult to the periphery or psy-
chological trauma. As such, the contribution of these additional
factors to the“clinical picture”of the animal following injury (e.g.,
functional deﬁcits and recovery) cannot be accurately accounted
for. From the other direction, it is possible to statistically control
for some of these variables (e.g., injury severity, age) in clinical
studies, but this still may not reduce the clinical case to that of an
animal model. Still in its early stages, blast-associated injury mod-
els range from those accounting for mechanisms of injury using
isolated spinal cord (Connell et al., 2011), to injury dosing in cell
cultures (Arun et al., 2011) to rodent models in which lethality,
pathophysiological markers of injury and functional deﬁcits can
be measured (Kuehn et al., 2011). The development of blast injury
models can beneﬁt from the many preceding decades in which
the study of animal models of non-blast TBI has been ﬁne-tuned
to include multiple behavioral measures of post-injury sequelae
and functional change over time, as well as the pathophysiological
markers associated with this temporal pattern.
MODELING OF PTSD: CHALLENGES AND LESSONS LEARNED
The complexity of PTSD, in terms of its symptoms and co-
morbidities would not appear to easily lend itself to being studied
in an animal model. However, because PTSD symptoms are fairly
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well-characterized, it has been possible to model certain aspects
or phenotypes of the disorder (Jovanovic and Norrholm, 2011;
Skelton et al., 2012). A good example of this is inhibition of fear
(or learning of safety signals), which has been extensively studied
in multiple species. Neurocircuitry has been elucidated in rodents
which appears to model the human condition. Moreover, when
the animal model protocol is tested in clinical populations it dis-
tinguishes between PTSD and depression (Jovanovic et al., 2010).
This successful translation of an animal model (fear potentiated
startle and inhibition of fear potentiated startle) to clinical study
(fear potentiated startle and fear inhibition), as well as the ongo-
ing research discourse between these is a welcome rarity. What
has yet to be developed, however, is a model that evokes lack of
fear inhibition after TBI. Once developed, such a model could also
serve as a vehicle for ongoing research discourse between bench
and bedside.
GUIDANCE REGARDING FUTURE EFFORTS
While the research on recovery from TBI within neuroscience may
be considered relatively “young,” (Rose and Johnson, 1992) there
have been enormous strides in the past three decades. Within
that time, recurrent themes have emerged including the impor-
tance of open and frequent interchange between the research in
animal models and that in humans, as well as the warning to
eschew the “silver bullet” approach to treatment (Kolb, 1992).
From these themes, it has become apparent that clinical trans-
lation from bench to bedside is not only important, but essential
to effectively understanding and developing treatments for mTBI
and/or PTSD.
CONCLUSION
Although advances are being made with respect to identifying
empirically supported assessment and treatment methods for
mTBI and/or PTSD, clinical needs continue to exceed current
knowledge. In terms of assessment, accurate, and feasible means
of facilitating differential diagnosis have yet to be identiﬁed. The
future of intervention research lies in examining both novel inter-
ventions and focusing on who beneﬁts from current evidence-
based practices and under what circumstances treatments are
most effective. Heterogeneity in the clinical presentation of those
returning from combat suggests that there is likely no “silver bul-
let.” For some, multi-dimensional and combination assessment
and treatment approaches are likely to be necessary. It is also
important to note that many returning warVeterans report symp-
toms often associated with mTBI and/or PTSD, but meet diagnos-
tic criteria for neither. As such, clinicians are being encouraged
to treat non-speciﬁc symptoms regardless of etiology (Brenner
et al., 2009). Based on such practices in the reality of the human
condition, animal scientists may want to consider focusing on
behavioral assessments that best capture clinical presentation, in
order to have a model of symptoms, which can then be the target
of treatment strategies. The high number of military personnel
being affected by blast injuries provides sufﬁcient clinical cases to
allow for parallel study of mTBI and/or PTSD in humans and ani-
mals.However, increased collaboration between scientistsworking
with animals and humans is required in order to maximize suc-
cessful translation of both clinical knowledge to the development
of animal models, and ﬁndings from animal models to clinical
practice.
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